<DOC>
	<DOCNO>NCT02906709</DOCNO>
	<brief_summary>This study examine efficacy omarigliptin 25 mg weekly compare placebo Japanese patient T2DM inadequate glycemic control insulin monotherapy addition diet exercise therapy . The primary hypothesis study omarigliptin 25 mg weekly provide great reduction hemoglobin A1C ( HbA1c ) compare placebo assess change baseline Week 16 [ Phase A ( double-blind period ) ] .</brief_summary>
	<brief_title>Omarigliptin Add-on Insulin Japanese Participants With Type 2 Diabetes Mellitus ( T2DM , MK-3102-039 )</brief_title>
	<detailed_description>After screen period 2 week follow pretreatment period 2 10 week , participant receiving assign double-blind treatment ( omarigliptin 25 mg placebo weekly ) approximately 16 week ( Phase A ) follow 36 week open-label treatment ( omarigliptin 25 mg weekly , Phase B ) . After end treatment participant follow 21 day .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Have T2DM Meet follow criterion Week 2 prerandomization 1 . On diet exercise therapy 6 week longer , AND 2 . Have stable dosage administration insulin ( 8 40 units/day ) 10 week longer , AND . 3 . Have additional antihyperglycemic agent ( AHAs , except insulin monotherapy ) 8 week longer , AND 4 . HbA1c ≥7.5 % ≤10.0 % 5 . FPG ≥126 mg/dL ≤230 mg/dL Have body mass index ( BMI ) &gt; 18 kg/m^2 &lt; 40 kg/m^2 A male female reproductive potential female reproductive potential agrees remain abstinent heterosexual activity , agree use acceptable contraception prevent pregnancy . Has type 1 diabetes mellitus history diabetic ketoacidosis . Has history administer follow AHAs include fix dose combination ( FDC ) contain follow ingredient : 1 . Thiazolidinediones within 12 week 2 . Glucagonlike peptide 1 ( GLP1 ) receptor agonist within 12 week 3 . Omarigliptin time Has history severe hypoglycemia coma loss consciousness , hypoglycemia observe great equal two time per week within 8 week Is currently participate participate another study investigational compound device within prior 12 week Has undergone surgical procedure within 8 week plan major surgery study . Receives lipidlowering medication thyroid replacement therapy unstable dosage administration Has poorly control hypertension Has medical history active liver disease , include chronic active hepatitis B C , primary biliary cirrhosis , symptomatic gallbladder disease . Has human immunodeficiency virus . Has new worsen sign symptom coronary heart disease congestive heart failure within past 3 month , acute coronary syndrome , coronary artery intervention , stroke transient ischemic neurological disorder within past 3 month Has severe peripheral vascular disease . Has history malignancy ≤ 5 year , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer : Has clinically important hematological disorder . ( For woman childbearing potential ) positive urine pregnancy test . Is pregnant breast feeding Is expect conceive study Is expect undergo hormonal therapy preparation donate egg study Routinely consumes &gt; 14 alcoholic drink per week engages binge drinking Has donate plan donate blood product &gt; 300 mL within 8 week study Has receive plan receive blood product within 12 week study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>